Variation in oral calcitriol response in patients with stages 3-4 CKD.

ABSTRACT:

Background

Oral calcitriol decreases parathyroid hormone (PTH) concentrations in patients who have chronic kidney disease (CKD); however, treatment response is highly variable. We evaluated whether patient characteristics affect the PTH response to oral calcitriol in nondialysis patients with CKD in a clinic-based setting.

Study design

Cohort study.

Setting & participants

This study included 379 new oral calcitriol users in the Veterans' Affairs Northwest Health Network. All had stages 3-4 CKD, hyperparathyroidism, and a serum PTH measurement before and 1-6 months after initiating oral calcitriol therapy.

Predictors

Patient-level characteristics hypothesized to affect calcitriol response: race, body size, concurrent medications, and kidney function.

Outcomes

SUBMITTER: Shoben AB 

PROVIDER: S-EPMC3328668 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature